Prior COVID‐19 vaccination and reduced risk of cerebrovascular diseases among COVID‐19 survivors

Journal of Medical Virology, Journal Year: 2024, Volume and Issue: 96(5)

Published: May 1, 2024

The effects of COVID-19 vaccination on short-term and long-term cerebrovascular risks among survivors remained unknown. We conducted a national multi-center retrospective cohort study with 151 597 vaccinated unvaccinated patients using the TriNetX database, from January 1, 2020 to December 31, 2023. Patients baseline characteristics were balanced propensity score matching (PSM). outcomes incident diseases occurred between 1st 30th days (short-term) after diagnosis. Nine subgroup analyses explore potential effect modifications. performed six sensitivity analyses, including evaluation 180th days, accounting for competing risk, incorporating different variant timeline test robustness our results. Kaplan-Meier curves Log-Rank tests evaluate survival difference. Cox proportional hazards regressions adopted estimate PSM-adjusted hazard ratios (HR). overall lower in group compared (HR: 0.66, 95% CI: 0.56-0.77), specifically cerebral infarction 0.62, 0.48-0.79), occlusion stenosis precerebral arteries 0.74, 0.53-0.98), other 0.57, 0.42-0.77), sequelae disease 0.39, CI:0.23-0.68). Similarly, those most subgroups. outcomes, though slightly attenuated, consistent 0.80, 0.73-0.87). Full 2-dose was associated further reduced risk 0.63, 0.50-0.80) patients. Unvaccinated have significantly higher than their counterparts. Thus, clinicians are recommended monitor this population closely stroke events during postinfection follow-up.

Language: Английский

---

Effects of COVID-19 and Influenza Vaccination on Rheumatic Diseases: Results From a Survey of Patient-Reported Outcomes After Vaccination

Journal of Korean Medical Science, Journal Year: 2023, Volume and Issue: 38(32)

Published: Jan. 1, 2023

This study aimed to compare the occurrence of adverse events (AEs) and disease flares after vaccination against coronavirus 2019 (COVID-19) influenza in patients with autoimmune rheumatic diseases (ARDs).Between November 2021 March 2022, a survey was conducted among ARD who received COVID-19 vaccinations. The questionnaire included 11 mandatory closed-ended questions, following items were collected: medical history, immunization type vaccine, patient-reported AEs, flare-up underlying vaccination, confirmed diagnosis or influenza. We compared vaccine-related reactions vaccines based on results. Multivariate logistic regression analysis used identify factors affecting AEs post-vaccine response mixed matched vaccines.We analyzed 601 adults mean age 49.6 years (80.5% female). A total 255 participants (42.4%) complete course primary 342 (56.9%) completed booster dose, 132 (38.6%) vaccine. frequencies (188 [52.2%] vs. 21 [5.8%]; P < 0.001) (58 [16.2%] 5 [1.4%]; significantly higher than those vaccination. In risk factor analysis, previous allergic reaction other (odds ratio, 1.95; confidence interval, 1.07-3.70; = 0.034) only associated AEs. There no difference responses between vaccines.The results revealed that receiving vaccine

Language: Английский

---

Factors related to acceptance of COVID-19 vaccine booster doses among patients with autoimmune and rheumatic diseases in Japan: A single-center cross-sectional survey

Modern Rheumatology, Journal Year: 2024, Volume and Issue: unknown

Published: Nov. 16, 2024

ABSTRACT Objectives We studied the current state and factors associated with acceptance or hesitancy of booster doses coronavirus disease 2019 (COVID-19) vaccine among patients autoimmune rheumatic diseases (ARDs) in Japan. Methods A single-centre cross-sectional survey was conducted outpatients ARDs who visited Immuno-Rheumatology Center at St. Luke’s International Hospital from 1 October 2023 to 30 November 2023. investigated patient characteristics, COVID-19 vaccination–related status, decision-making preferences, health-related independent vaccine. Results total 241 were included analyses, 198 (82.2%) received doses, while 43 (17.8%) did not. Older age [adjusted odds ratio (aOR) = 0.43, 95% confidence interval (CI): 0.19, 0.95, P .037], having rheumatoid arthritis (aOR 0.41, CI: 0.92, .030), a physician recommend receiving 0.47, 0.23, .035) independently doses. The main reasons for regarding concerns about adverse reactions long-term safety. Conclusions Our findings could help physicians counsel their promote appropriate decision-making.

Language: Английский

---

The Modern Epidemic of Autoimmunity

International Journal of Rheumatic Diseases, Journal Year: 2024, Volume and Issue: 27(11)

Published: Nov. 1, 2024

ABSTRACT Autoimmunity occurs when the immune system mistakenly attacks body, but presence of autoantibodies, such as antinuclear antibodies (ANAs), does not always lead to autoimmune diseases. Globally, autoimmunity is on rise, influenced by socioeconomic factors, environmental exposure, diet, and stress. Climate change pollution further exacerbate risks. The COVID‐19 pandemic has worsened issue, with unvaccinated individuals showing higher rates conditions postinfection. Preventive strategies, including healthy diets, stress management, vaccination, are crucial in combating this growing epidemic. Collaboration between individuals, healthcare providers, policymakers critical mitigate rise disorders enhance public health.

Language: Английский

---